These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 20664555)

  • 1. Angiotensin II receptor blockade with valsartan decreases plasma osteopontin levels in patients with essential hypertension.
    Kurata M; Okura T; Irita J; Enomoto D; Nagao T; Jotoku M; Miyoshi K; Desilva VR; Higaki J
    J Hum Hypertens; 2011 May; 25(5):334-9. PubMed ID: 20664555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between osteopontin and adiponectin in patients with essential hypertension.
    Kurata M; Okura T; Irita J; Enomoto D; Nagao T; Jotoku M; Miyoshi K; Higaki J
    Clin Exp Hypertens; 2010; 32(6):358-63. PubMed ID: 21028999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
    Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
    Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.
    Zanchetti A; Julius S; Kjeldsen S; McInnes GT; Hua T; Weber M; Laragh JH; Plat F; Battegay E; Calvo-Vargas C; Cieśliński A; Degaute JP; Holwerda NJ; Kobalava J; Pedersen OL; Rudyatmoko FP; Siamopoulos KC; Störset O
    J Hypertens; 2006 Nov; 24(11):2163-8. PubMed ID: 17053536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of valsartan with or without benazepril on blood pressure, angiotensin II, and endoxin in patients with essential hypertension.
    Ke YS; Tao YY; Yang H; Yu GH
    Acta Pharmacol Sin; 2003 Apr; 24(4):337-41. PubMed ID: 12676074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.
    Corea L; Cardoni O; Fogari R; Innocenti P; Porcellati C; Provvidenza M; Meilenbrock S; Sullivan J; Bodin F
    Clin Pharmacol Ther; 1996 Sep; 60(3):341-6. PubMed ID: 8841157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients.
    Nakamura T; Fujii S; Hoshino J; Saito Y; Mizuno H; Saito Y; Kurabayashi M
    Hypertens Res; 2005 Dec; 28(12):937-43. PubMed ID: 16671331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
    Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
    Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients.
    Fogari R; Zoppi A; Derosa G; Mugellini A; Lazzari P; Rinaldi A; Fogari E; Preti P
    J Hum Hypertens; 2007 Mar; 21(3):220-4. PubMed ID: 17215848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The comparative effects of valsartan and amlodipine on vascular microinflammation in newly diagnosed hypertensive patients.
    Unlu M; Karaman M; Ay SA; Balta S; Cakar M; Demirkol S; Celik T; Arslan E; Demirbas S; Turker T; Yaman H; Bulucu F; Sağlam K
    Clin Exp Hypertens; 2013; 35(6):418-23. PubMed ID: 23148500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients.
    Fogari R; Malamani G; Corradi L; Mugellini A; Preti P; Zoppi A; Derosa G
    Adv Ther; 2010 Jan; 27(1):48-55. PubMed ID: 20174905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential time effect profiles of amlodipine, as compared to valsartan, revealed by ambulatory blood pressure monitoring, self blood pressure measurements and dose omission protocol.
    Radauceanu A; Boivin JM; Bernaud C; Fay R; Zannad F;
    Fundam Clin Pharmacol; 2004 Aug; 18(4):483-91. PubMed ID: 15312156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of valsartan and indapamide on plasma cytokines in essential hypertension.
    Xie QY; Wang YJ; Sun ZL; Yang TL
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):629-34. PubMed ID: 17062919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C; Croce G; Desideri G
    Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients.
    Munakata M; Nagasaki A; Nunokawa T; Sakuma T; Kato H; Yoshinaga K; Toyota T
    Am J Hypertens; 2004 Nov; 17(11 Pt 1):1050-5. PubMed ID: 15533733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy.
    Brachmann J; Ansari A; Mahla G; Handrock R; Klebs S
    Adv Ther; 2008 May; 25(5):399-411. PubMed ID: 18465097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
    Andrés A; Morales E; Morales JM; Bosch I; Campo C; Ruilope LM;
    Transplant Proc; 2006 Oct; 38(8):2419-23. PubMed ID: 17097955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.